Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
Nxera Pharma secured a $10 million milestone payment from Neurocrine Biosciences following IND acceptance for NBI-1117567 in a Phase 2 study. This funding will enhance Nxera's drug development initiatives.
Aug 26, 2026•about 4 hours ago
TokyoBiotechnologyPharmaceutical
Description
Nxera Pharma has announced that it will receive a $10 million milestone payment from its partner Neurocrine Biosciences upon IND acceptance for the Phase 2 study of NBI-1117567. This milestone payment marks a significant advancement in Nxera's drug portfolio aimed at Alzheimer's cognition. The funds are expected to be recognized as revenue in Q3 FY2026. This development demonstrates Nxera's commitment to addressing significant medical needs in the field of Alzheimer's treatment.
Company Information
Company
Nxera Pharma Ltd
Location
Tokyo, Tokyo, Japan
About
Nxera Pharma (formerly Sosei Heptares) is a technology powered biopharma company, in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally.
In addition to several products being commercialized in Japan, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across neurology, GI and immunology, metabolic disorders and rare diseases, and leverages the power of our unique and industry leading GPCR-targeted structure-based drug discovery “NxWave” platform to provide a sustainable source of best- or first-in-class candidates.
TokyoBiotechnologyPharmaceutical